<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02863471</url>
  </required_header>
  <id_info>
    <org_study_id>PanHIPEC</org_study_id>
    <nct_id>NCT02863471</nct_id>
  </id_info>
  <brief_title>Study on Hyperthermic Intraperitoneal Chemotherapy After Resection of Pancreascarcinoma</brief_title>
  <acronym>PanHIPEC</acronym>
  <official_title>Open-label Pilot Phase I / II Study on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Macroscopically Complete Resection (R0/R1) of Adenocarcinomas of the Pancreas (PanHIPEC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with peritoneal metastases of colorectal cancer could be a radical removal of all&#xD;
      tumor foci a significantly improved survival compared to a sole systemic chemotherapy are&#xD;
      additionally achieved by a hyperthermic intraoperative chemotherapy (HIPEC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite medical progress in recent years in pancreatic reach the 5-year survival rates even&#xD;
      after radical surgical resection only 20%, which is due to high rates of local recurrence and&#xD;
      distant metastases in the postoperative course. Due to the anatomical position of the&#xD;
      pancreas resections are having a &quot;wide margin&quot; technically almost impossible, so that the&#xD;
      tumor on postoperative preparation is often marginal forming. A further possible explanation&#xD;
      for the high number of local recurrences, intraoperative tumor cell displacement in question.&#xD;
&#xD;
      In patients with peritoneal metastases of colorectal cancer could be a radical removal of all&#xD;
      tumor foci a significantly improved survival compared to a sole systemic chemotherapy are&#xD;
      additionally achieved by a hyperthermic intraoperative chemotherapy (HIPEC). Purpose of HIPEC&#xD;
      it is to kill any remaining microscopic residual tumor or residual tumor cells free. The aim&#xD;
      of the present phase I / II study is therefore to examine the importance of HIPEC in addition&#xD;
      to radical resection of ductal pancreatic cancer in terms of mortality and morbidity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 days mortality after macroscopically complete Resection ( R0 / R1 ) of an adenocarcinoma of the pancreas in combined with hyperthermic intraperitoneal chemotherapy (HIPEC)</measure>
    <time_frame>day 30</time_frame>
    <description>Safety according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>day 30</time_frame>
    <description>Safety according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>day 30</time_frame>
    <description>Safety according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea</measure>
    <time_frame>day 30</time_frame>
    <description>Safety according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stomatitis</measure>
    <time_frame>day 30</time_frame>
    <description>Safety according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hair loss</measure>
    <time_frame>day 30</time_frame>
    <description>Safety according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophilia</measure>
    <time_frame>day 30</time_frame>
    <description>Safety according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombocytopenia</measure>
    <time_frame>day 30</time_frame>
    <description>Safety according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Adenocarcinomas of the Pancreas</condition>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 milligram (mg)/ square meter (m²) body surface, intraperitoneal use, unique intraoperative application for 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage</description>
    <arm_group_label>Gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Computertomographic (CT) morphologically suspected pancreatic tumor without distant&#xD;
             metastases, with the possibility of a macroscopically complete resection residual&#xD;
             tumor classification (R) R0 / R1 .&#xD;
&#xD;
          -  Histological diagnosis of adenocarcinoma of the pancreas' in the frozen section&#xD;
             intraoperatively&#xD;
&#xD;
          -  Karnofsky Index &gt; 70&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are considered inoperable because of reduced general&#xD;
&#xD;
          -  Congestive heart failure New York Heart Association (NYHA) III / IV&#xD;
&#xD;
          -  Severe coronary heart disease, non-treatable arrhythmia or nonadjustable hypertension,&#xD;
&#xD;
          -  Severe asthma suffering, chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine ≥ 1.5 x of normal, or creatinine clearance &lt;60&#xD;
             milliliter (ml) / minutes (min))&#xD;
&#xD;
          -  Patients where the intra-operative frozen section no adenocarcinoma of the pancreas&#xD;
             can be demonstrated&#xD;
&#xD;
          -  Patients suffering from a second malignancy (within 5 years in the study of consent)&#xD;
             except basal cell carcinoma and curative treated insitu carcinoma of the cervix&#xD;
&#xD;
          -  Distant metastases (M) &gt; 0&#xD;
&#xD;
          -  Patients with a contraindication related to the present study&#xD;
&#xD;
          -  Allergy or intolerance to the study drug or a substance with chemical similarity to&#xD;
             the study medication.&#xD;
&#xD;
          -  Patients under legal custodianship or incarcerated patients&#xD;
&#xD;
          -  Patients that can not understand the purpose of the study due to mental, intellectual&#xD;
             or linguistic problem&#xD;
&#xD;
          -  Participation in Clinical Trials or other observation period of competing trials.&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) that do not agree&#xD;
&#xD;
               -  To utilize two reliable forms of contraception or practice complete abstinence&#xD;
                  from Simultaneously heterosexual contact for at least 28 days before start of&#xD;
                  treatment and for at least 28 days after administration of study treatment&#xD;
&#xD;
               -  To abstain from breastfeeding during study participation and 6 months after study&#xD;
                  treatment.&#xD;
&#xD;
          -  Males that do not agree&#xD;
&#xD;
               -  to use a latex condom during any sexual contact with FCBP during participation in&#xD;
                  the study and for at least 28 days study following treatment, even if he has&#xD;
                  undergone a successful vasectomy&#xD;
&#xD;
               -  to refrain from donating semen or sperm for at least 28 days after study&#xD;
                  treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Beckert, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Department of General, Visceral and TransplantSurgery Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Beckert, Prof. Dr.</last_name>
    <phone>+49-7071-2981222</phone>
    <email>stefan.beckert@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alfred Königsrainer, Prof. Dr.</last_name>
    <phone>+49-7071-2986619</phone>
    <email>alfred.koenigsrainer@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Beckert, Prof. Dr.</last_name>
      <phone>+49-7071-2981222</phone>
      <email>stefan.beckert@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Alfred Königsrainer, Prof. Dr.</last_name>
      <phone>+49-7071-2986619</phone>
      <email>alfred.koenigsrainer@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Hyperthermic intraperitoneal chemotherapy</keyword>
  <keyword>HIPEC</keyword>
  <keyword>Pancreatic surgery</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

